|
| 37980367 | Phase 1b study of enzalutamide plus CC-115, a dual mTORC1/2 and DNA-PK inhibitor, in men with metastatic castration-resistant prostate cancer (mCRPC). | Br J Cancer | 2024 |
| 36115772 | Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer. | Eur Urol | 2023 |
| 37845474 | Neoplasia risk in patients with Lynch syndrome treated with immune checkpoint blockade. | Nat Med | 2023 |
| 36952634 | Niraparib and Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer. | J Clin Oncol | 2023 |
| 37040594 | External Validation of a Prognostic Model of Overall Survival in Men With Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer. | J Clin Oncol | 2023 |
| 37003085 | Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. | Eur J Cancer | 2023 |
| 37399894 | Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial. | Ann Oncol | 2023 |
| 36494221 | Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. | Eur Urol | 2023 |
| 34667026 | Differences in Prostate Cancer Genomes by Self-reported Race: Contributions of Genetic Ancestry, Modifiable Cancer Risk Factors, and Clinical Factors. | Clin Cancer Res | 2022 |
| 35440417 | Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [Eur Urol 82(1):6-11]. | Eur Urol | 2022 |
| 35538298 | Clinical annotations for prostate cancer research: Defining data elements, creating a reproducible analytical pipeline, and assessing data quality. | Prostate | 2022 |
| 35568679 | Effects of metformin and statins on outcomes in men with castration-resistant metastatic prostate cancer: Secondary analysis of COU-AA-301 and COU-AA-302. | Eur J Cancer | 2022 |
| 35450732 | Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. | Eur Urol | 2022 |
| 36317634 | A clinical-grade liquid biomarker detects neuroendocrine differentiation in prostate cancer. | J Clin Invest | 2022 |
| 35013615 | Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial. | Nat Med | 2022 |
| 35247924 | A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors. | Clin Cancer Res | 2022 |
| 34973233 | Radiographic progression-free survival in the ACIS trial for prostate cancer - Authors' reply. | Lancet Oncol | 2022 |
| 35020444 | Dermatological Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor Apalutamide. | J Urol | 2022 |
| 34088618 | A Phase II, Nonrandomized Open Trial Assessing Pain Efficacy with Radium-223 in Symptomatic Metastatic Castration-resistant Prostate Cancer. | Clin Genitourin Cancer | 2021 |
| 33683939 | Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer. | J Urol | 2021 |
| 33785848 | Correction: Treating the patient and not just the cancer: therapeutic burden in prostate cancer. | Prostate Cancer Prostatic Dis | 2021 |
| 33579638 | Genitourinary Medical Oncology Expert Opinion Survey Regarding Treatment Management in the COVID-19 Pandemic. | Clin Genitourin Cancer | 2021 |
| 33603236 | Treating the patient and not just the cancer: therapeutic burden in prostate cancer. | Prostate Cancer Prostatic Dis | 2021 |
| 35071831 | Evaluating the Role of Stereotactic Body Radiation Therapy With Respect to Androgen Receptor Signaling Inhibitors for Oligometastatic Prostate Cancer. | Adv Radiat Oncol | 2021 |
| 34600602 | Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study. | Lancet Oncol | 2021 |
| 34059130 | Tumor fraction-guided cell-free DNA profiling in metastatic solid tumor patients. | Genome Med | 2021 |
| 34197212 | Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. | J Clin Oncol | 2021 |
| 32317181 | Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics. | Eur Urol | 2020 |
| 34258585 | Accelerating precision medicine in metastatic prostate cancer. | Nat Cancer | 2020 |
| 32057715 | A Phase I Trial of IGF-1R Inhibitor Cixutumumab and mTOR Inhibitor Temsirolimus in Metastatic Castration-resistant Prostate Cancer. | Clin Genitourin Cancer | 2020 |
| 32856010 | Platinum-Based Chemotherapy in Metastatic Prostate Cancer With DNA Repair Gene Alterations. | JCO Precis Oncol | 2020 |
| 32679108 | Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer. | Cancer Cell | 2020 |
| 32847933 | Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study. | Clin Cancer Res | 2020 |
| 30589920 | Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. | JAMA Oncol | 2019 |
| 31853198 | First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy. | Cancer Manag Res | 2019 |
| 31266833 | Pleiotropic Impact of DNA-PK in Cancer and Implications for Therapeutic Strategies. | Clin Cancer Res | 2019 |
| 31266829 | DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway. | Clin Cancer Res | 2019 |
| 30725389 | A phase I study of the antibody drug conjugate ASG-5ME, an SLC44A4-targeting antibody carrying auristatin E, in metastatic castration-resistant prostate cancer. | Invest New Drugs | 2019 |
| 30691365 | Treatment of Advanced Prostate Cancer. | Annu Rev Med | 2019 |
| 29088323 | Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet. | Ann Oncol | 2018 |
| 30101644 | Apalutamide for the treatment of prostate cancer. | Expert Rev Anticancer Ther | 2018 |
| 29522174 | Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer: The PREVAIL Randomized Clinical Trial. | JAMA Oncol | 2018 |
| 29608397 | Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline. | J Clin Oncol | 2018 |
| 29508246 | A phase II study of the dual mTOR inhibitor MLN0128 in patients with metastatic castration resistant prostate cancer. | Invest New Drugs | 2018 |
| 27402060 | Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. | Eur Urol | 2017 |
| 28314611 | Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. | Eur Urol | 2017 |
| 28213364 | Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone. | Clin Cancer Res | 2017 |
| 28117385 | Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. | Prostate Cancer Prostatic Dis | 2017 |
| 28825054 | Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making. | JCO Precis Oncol | 2017 |
| 28633425 | Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide. | Ann Oncol | 2017 |